Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 29, 2024
Open Peer Review Period: Mar 1, 2024 - Apr 26, 2024
Date Accepted: Aug 30, 2024
(closed for review but you can still tweet)
Title: Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: A Systematic Review Protocol
ABSTRACT
Background:
Monitoring of various clinical outcomes and parameters such as lipid levels is recommended in transgender individuals undergoing hormone therapies. However, comprehensive data to inform these recommendations is scarce.
Objective:
This systematic review and meta-analysis aim to synthesize evidence from existing literature on the effect of exogenous hormone therapy on clinical and biochemical outcomes for transgender adolescents and adults.
Methods:
We will search multiple electronic databases and will include prospective and retrospective observational studies with and without a control group. The study population will include transgender individuals undergoing hormone therapy with testosterone or estrogen. Comparisons will include age-matched, cisgender individuals and changes from baseline. Primary outcomes include changes in and/or the development of abnormal lipid parameters. Secondary outcomes include body mass index, weight, height, and blood pressure for age, serum testosterone or estrogen levels, and development of disease including hypertension, diabetes, fatty liver disease, obesity, adverse cardiac events, as well as all-cause mortality. The meta-analysis will pool the studies where applicable, and meta-regressions will be conducted to evaluate effect modifiers. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach will be used to evaluate the overall certainty of evidence.
Results:
We will summarize the selection of the eligible studies using a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. The results will be presented in a table summarizing the evidence.
Conclusions:
This systematic review will summarize and evaluate the evidence of the clinical and biochemical outcomes associated with hormone therapies for transgender individuals. Clinical Trial: Prospero registration number: CRD42024483138
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.